Frank Sasinowki, Director at Hyman, Phelps & McNamara, P.C. and board member of the National Organization for Rare Disorders ("NORD"), is giving the keynote address for the Campaign Urging Research for Eosinophilic Disease’s ("CURED’s") first research symposium on eosinophilic gastrointestinal disorders ("EGID"). CURED is a non-profit foundation dedicated to helping individuals suffering from rare eosinophilic disorders by raising funds for research and increasing public awareness. The first EGID symposium begins on November 2nd and runs through November 3rd at the Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio. The symposium has several objectives, one of which is to discuss potential pathways to develop drugs for the treatment of eosinophilic disorders.
Mr. Sasinowski’s November 2nd keynote presentation will focus on drug development issues relevant to rare conditions such as eosinophilic disorders, including:
- Current FDA policies related to rare diseases;
- FDA flexibility in reviewing orphan drugs (see here);
- The role of patients in drug development in light of the Food and Drug Administration Safety and Innovation Act (FDASIA); and
- The President’s Council of Advisors on Science and Technology ("PCAST") report (see here), its recommendations to accelerate drug development and approval, and Mr. Sasinowki’s important contributions to that effort.